Related Experiment Video
Updated: May 20, 2026
06:07
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
Weight gain in smokers after quitting cigarettes: meta-analysis.
Henri-Jean Aubin1, Amanda Farley, Deborah Lycett
1Centre d'Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, AP-HP, Univ Paris-Sud, INSERM U669, 94804 Villejuif, France. henri-jean.aubin@pbr.aphp.fr
BMJ (Clinical Research Ed.)
|July 12, 2012
Summary
Smoking cessation leads to an average weight gain of 4-5 kg within 12 months, with most occurring in the first three months. Weight changes vary significantly among individuals who quit smoking.
Area of Science:
- Public Health
- Addiction Medicine
- Behavioral Science
Background:
- Smoking cessation is a key public health goal.
- Weight gain is a common concern for individuals attempting to quit smoking.
- Understanding weight change patterns is crucial for supporting long-term abstinence.
Purpose of the Study:
- To quantify weight gain in smokers achieving prolonged abstinence up to 12 months.
- To analyze weight variation in individuals quitting with or without cessation aids.
- To describe the trajectory of weight change post-smoking cessation.
Main Methods:
- A meta-analysis of 62 randomized controlled trials.
- Inclusion criteria focused on studies reporting weight change in abstinent smokers.
- Random effects models were used to calculate mean weight change and explore subgroup differences.
Main Results:
- Untreated quitters gained an average of 4.67 kg at 12 months post-cessation.
- Most weight gain (over 4 kg) occurred within the first three months.
- Weight gain patterns were similar across different cessation pharmacotherapies and levels of concern about weight gain.
Conclusions:
- Smoking cessation is associated with a significant mean weight increase of 4-5 kg after one year.
- The majority of weight gain happens early in the cessation process.
- There is considerable individual variation in weight change, with some quitters losing weight and others gaining substantially.
Related Concept Videos
01:26Stress Prevention and Stress Management Techniques IV
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
01:25Statistical Methods for Analyzing Epidemiological Data
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...